Compare Enveric Biosciences Inc (ENVB) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Roundhill Magnificent Seven ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Roundhill Magnificent Seven ETF trades at $68.4. The key difference: Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | MAGS | |
|---|---|---|
Market Cap | $6.20M | — |
Sector | Health | Sector/Thematic |
52-Week High | $17.40 | $70.94 |
52-Week Low | $1.27 | $55.39 |
Enterprise Value | $1.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
MAGS trades at $69.07, up 0.71% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights underperformance versus the S&P 500 and concerns over AI spending pressure on big tech balance sheets. The ETF has gained 181% since launch but faces challenges from equal-weighted concentration in the Magnificent Seven stocks.
The outlook is mixed: technical strength supports near-term upside, but fundamental risks from high AI capital expenditure and shifting investor sentiment toward broader market exposure pose headwinds. Investment opportunity hinges on AI revenue growth outpacing costs, while key risks include sector rotation and valuation compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
